Samit Hirawat

9.6k total citations · 1 hit paper
55 papers, 3.8k citations indexed

About

Samit Hirawat is a scholar working on Pulmonary and Respiratory Medicine, Molecular Biology and Oncology. According to data from OpenAlex, Samit Hirawat has authored 55 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 35 papers in Pulmonary and Respiratory Medicine, 27 papers in Molecular Biology and 21 papers in Oncology. Recurrent topics in Samit Hirawat's work include Advanced Breast Cancer Therapies (19 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Cancer Treatment and Pharmacology (8 papers). Samit Hirawat is often cited by papers focused on Advanced Breast Cancer Therapies (19 papers), PI3K/AKT/mTOR signaling in cancer (10 papers) and Cancer Treatment and Pharmacology (8 papers). Samit Hirawat collaborates with scholars based in United States, Switzerland and France. Samit Hirawat's co-authors include Gary Elfring, Pierfranco Conté, Mario Campone, Yen‐Shen Lu, Kenichi Inoue, Eva Ciruelos, Sibylle Loibl, Gábor Rubovszky, Hope S. Rugo and Ingrid A. Mayer and has published in prestigious journals such as New England Journal of Medicine, Proceedings of the National Academy of Sciences and The Lancet.

In The Last Decade

Samit Hirawat

53 papers receiving 3.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer

2019 1.6k citations Fabrice André, Eva Ciruelos et al. New England Journal of Medicine profile →

Peers

Samit Hirawat

PRM

ONCOL

GENET

Maria Pik Wong Hong Kong

Prakash Chinnaiyan United States

Sandra S. McAllister United States

Peter Bugert Germany

Jake June-Koo Lee South Korea

Sílvia Menéndez United States

Cristina Nadal Spain

Tiago C. Silva United States

Geoffrey T. Gibney United States

Juan Manuel Sepúlveda-Sánchez Spain

Maria Pik Wong Hong Kong

Samit Hirawat

1.9k ×1.0

1.3k ×0.8

PRM

1.7k ×1.3

ONCOL

873 ×1.1

178 ×0.3

GENET

Citations per year, relative to Samit Hirawat Samit Hirawat (= 1×) peers Maria Pik Wong

Countries citing papers authored by Samit Hirawat

Since Specialization

Citations

This map shows the geographic impact of Samit Hirawat's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samit Hirawat with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samit Hirawat more than expected).

Fields of papers citing papers by Samit Hirawat

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samit Hirawat. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samit Hirawat. The network helps show where Samit Hirawat may publish in the future.

Co-authorship network of co-authors of Samit Hirawat

This figure shows the co-authorship network connecting the top 25 collaborators of Samit Hirawat. A scholar is included among the top collaborators of Samit Hirawat based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samit Hirawat. Samit Hirawat is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

André, Fabrice, Eva Ciruelos, Gábor Rubovszky, et al.. (2019). Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer. New England Journal of Medicine. 380(20). 1929–1940. 1565 indexed citations breakdown →

André, Fabrice, Eva Ciruelos, Gábor Rubovszky, et al.. (2018). Alpelisib (ALP) + fulvestrant (FUL) for advanced breast cancer (ABC): Results of the phase III SOLAR-1 trial. Annals of Oncology. 29. viii709–viii709. 53 indexed citations

Sellami, Dalila, et al.. (2017). Circulating tumor DNA as a novel tool to shape clinical trial designs with the potential to impact outcomes: a focus on PI3K inhibitors. Annals of Oncology. 28(11). 2882–2887. 8 indexed citations

Germa, Caroline, Michelle C. Miller, Pabak Mukhopadhyay, et al.. (2017). Discovery and development of novel therapies in advanced breast cancer: rapid development of ribociclib. Annals of Oncology. 28(8). 2021–2024. 6 indexed citations

Massacesi, Cristian, Emmanuelle di Tomaso, Patrick Urban, et al.. (2016). PI3K inhibitors as new cancer therapeutics: implications for clinical trial design. OncoTargets and Therapy. 9. 203–203. 195 indexed citations

O’Brien, Neil A., Tong Luo, Erika von Euw, et al.. (2014). Targeting PI3K/mTOR Overcomes Resistance to HER2-Targeted Therapy Independent of Feedback Activation of AKT. Clinical Cancer Research. 20(13). 3507–3520. 93 indexed citations

Saura, Cristina, Johanna C. Bendell, Guy Jérusalem, et al.. (2014). Phase Ib Study of Buparlisib plus Trastuzumab in Patients with HER2-Positive Advanced or Metastatic Breast Cancer That Has Progressed on Trastuzumab-Based Therapy. Clinical Cancer Research. 20(7). 1935–1945. 110 indexed citations

Massacesi, Cristian, Emmanuelle di Tomaso, Nathalie Fretault, & Samit Hirawat. (2013). Challenges in the clinical development of PI3K inhibitors. Annals of the New York Academy of Sciences. 1280(1). 19–23. 34 indexed citations

Wilschanski, Michael, L.L. Miller, David Shoseyov, et al.. (2011). Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. European Respiratory Journal. 38(1). 59–69. 151 indexed citations

10.

Kerem, Eitan, Michael Wilschanski, Thea Pugatsch, et al.. (2011). Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis. Journal of Cystic Fibrosis. 10(3). 193–200. 11 indexed citations

11.

Radford, John, Andrew Davies, Martin J.S. Dyer, et al.. (2010). Efficacy of panobinostat in phase II study in patients with relapsed/refractory Hodgkin lymphoma (HL) after high-dose chemotherapy with autologous stem cell transplant. British Journal of Haematology. 149. 2–3. 1 indexed citations

12.

Sermet‐Gaudelus, Isabelle, K. De Boeck, Georges Casimir, et al.. (2010). Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 182(10). 1262–1272. 184 indexed citations

13.

Clive, Sally, et al.. (2009). Elucidation of the metabolic and elimination pathways of panobinostat (LBH589) using [¹⁴C]-panobinostat. Journal of Clinical Oncology. 27(15_suppl). 2549–2549. 8 indexed citations

14.

McDonald, Craig M., Erik Henricson, Jay J. Han, et al.. (2009). The 6‐minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle & Nerve. 41(4). 500–510. 283 indexed citations

15.

Bernengo, M.G., F. Vanaclocha, Madeleine Duvic, et al.. (2008). A Phase Ii International, Multicenter Study of Oral Panobinostat (lbh589) in Patients With Refractory Cutaneous T-cell Lymphoma (ctcl). DIAL (Catholic University of Leuven). 93. 109. 1 indexed citations

16.

Kerem, Eitan, Samit Hirawat, S. Armoni, et al.. (2008). Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. The Lancet. 372(9640). 719–727. 290 indexed citations

17.

Finkel, Richard S., Brenda Wong, Kevin M. Flanigan, et al.. (2007). G.P.3.05 Phase 2 study of PTC124 for nonsense mutation suppression therapy of Duchenne muscular dystrophy (DMD). Neuromuscular Disorders. 17(9-10). 783–783. 7 indexed citations

18.

Hirawat, Samit, Ellen Welch, Gary Elfring, et al.. (2007). Safety, Tolerability, and Pharmacokinetics of PTC124, a Nonaminoglycoside Nonsense Mutation Suppressor, Following Single‐ and Multiple‐Dose Administration to Healthy Male and Female Adult Volunteers. The Journal of Clinical Pharmacology. 47(4). 430–444. 188 indexed citations

19.

Hirawat, Samit, Jonathan E. Kolitz, Stuart M. Lichtman, et al.. (2007). A Phase I Dose-Finding Study Using an Innovative Sequential Biweekly Schedule of Irinotecan Followed 24 Hours Later by Capecitabine. Cancer Investigation. 25(3). 148–153. 1 indexed citations

20.

Hirawat, Samit, Stuart M. Lichtman, & Steven L. Allen. (2001). Recombinant human erythropoietin use in hemolytic anemia due to prosthetic heart valves: A promising treatment. American Journal of Hematology. 66(3). 224–226. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact